Printer Friendly
The Free Library
19,607,059 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

BioScrip Sets Second Quarter 2005 Financial Release Date and Conference Call.


ELMSFORD, N.Y. & MINNEAPOLIS -- BioScrip, Inc. (NASDAQ NASDAQ
 in full National Association of Securities Dealers Automated Quotations

U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on
:BIOS), will release second quarter 2005 financial results on Thursday, August 4, 2005 before the market opens.

BioScrip will host a conference call to discuss results on Thursday, August 4, 2005 at 10:00 a.m. EDT EDT
abbr.
Eastern Daylight Time


EDT Eastern Daylight Time

EDT n abbr (US) (= Eastern Daylight Time) → hora de verano de Nueva York

EDT 
. To participate in the conference call, dial 212-231-6027 at least 5-10 minutes prior to the scheduled time, and follow the operator's instructions. This call will also be webcast live over the Internet. To participate, please logon to our website at www.bioscrip.com.

If you are unable to join us live, the call will be archived on our website. In addition, a recording of the conference call will be available through an instant replay service beginning at 12:00 p.m. EDT on August 4, 2005 through 12:00 p.m. EDT on August 11, 2005. To access the replay during this period, call 800-633-8284 or 402-977-9140 and enter the reservation number 21252717.

About BioScrip, Inc.

BioScrip, Inc. was formed March 12, 2005 from the merger of MIM MIM Metal Injection Molding
MIM Mendelian Inheritance in Man
MIM Mobile Instant-Messaging
MIM Man in the Middle
MIM Multilateral Initiative on Malaria
MIM Metal-Insulator-Metal
MIM Master of International Management
MIM Made in Mexico
 Corporation and Chronimed Inc. BioScrip provides comprehensive pharmaceutical care solutions. We partner with healthcare payors, pharmaceutical manufacturers, government agencies, physicians, and patients to deliver cost effective programs that enhance the quality of patient life. We focus our products and services in two core areas: Specialty medication distribution and clinical management services, both nationally and community-based and Pharmacy Benefit Management A Pharmacy Benefit Manager (PBM) is a third party administrator of prescription drug programs. They are primarily responsible for processing and paying prescription drug claims.  services. Our specialty medication distribution capabilities include condition-specific clinical management programs tailored to improve the care of individuals with complex health conditions such as HIV/AIDS HIV/AIDS Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome , Cancer, Infusion IVIG IVIG Intravenous immunoglobulin, see there , Hepatitis C Hepatitis C Definition

Hepatitis C is a form of liver inflammation that causes primarily a long-lasting (chronic) disease. Acute (newly developed) hepatitis C is rarely observed as the early disease is generally quite mild.
, Rheumatoid Arthritis, Multiple Sclerosis, and Transplantation. Our complete pharmacy benefit management programs include customized benefit plan design, pharmacy network management and sophisticated reporting capabilities that deliver improved clinical and economic outcomes. In addition, we have 30 retail locations in 25 major metropolitan markets across the U.S., providing nationwide access and clinical management capabilities in a high-touch community-based environment.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jul 29, 2005
Words:321
Previous Article:MacWest Opens Riverside Senior Apartments.
Next Article:Fitch Rts The Unified Gov of Wyandotte County, Kansas City, KS 1st Lien Bnds Ser 05A, B, C 'AA+'.



Related Articles
BioScrip Sets First Quarter 2005 Financial Release Date and Conference Call.
BioScrip Announces First Quarter Financial Results.
BioScrip Announces Second Quarter Financial Results; Reports $6.6 Million of Special Charges Related to Merger and Re-Branding Efforts.
BioScrip Sets Third Quarter 2005 Financial Release Date and Conference Call.
BioScrip Announces Third Quarter Financial Results.
BioScrip Announces Fourth Quarter and Calendar Year 2005 Financial Results; Strategic Focus on Realizing Synergies and the Potential of Dynamic Drug...
BioScrip Announces First Quarter 2006 Financial Results; Revenues in Line with Expectations.
BioScrip Announces Second Quarter 2006 Financial Results; Cost Reduction Program Moving Forward; Concentrating on New Product and Infusion Expansion,...
BioScrip Announces Third Quarter 2006 Financial Results.
BioScrip, Inc. Announces 2006 Fourth Quarter and Year-End Results.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles